Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53

Benzinga Newsdesk www.benzinga.com Neutral 64.9%

Neg 0% Neu 64.9% Pos 0%

Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.